TP53 and neoplasm: Together, these data suggest a possible enrichment for response in TP53-mutant; KRASG12 WT tumours (6 of 13; 46%; Fig. 2f) compared with limited responses in TP53-mutant;KRASG12-mutant tumours (1 of 7, 14%) and TP53 WT;KRASG12-mutant tumours (0 of 7, 0%).